• 1. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 2. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 3. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 4. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 5. Fe3O4/FeS2 heterostructures enable efficient oxygen evolution reaction?
  Xingqun Zheng,Lele Song,Xin Feng,Li Li,Zidong Wei J. Mater. Chem. A, 2020,8, 14145-14151

Introduction to 5-(chloromethyl)-1-(2,2-difluoroethyl)-1H-pyrazole (CAS No. 1296225-29-0)

5-(chloromethyl)-1-(2,2-difluoroethyl)-1H-pyrazole, identified by its CAS number 1296225-29-0, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical and chemical research. This compound belongs to the pyrazole class, a heterocyclic structure known for its broad range of biological activities and applications in medicinal chemistry. The presence of both chloromethyl and difluoroethyl substituents in its molecular framework imparts unique chemical properties, making it a valuable intermediate in the synthesis of various pharmacologically active molecules.

The molecular structure of 5-(chloromethyl)-1-(2,2-difluoroethyl)-1H-pyrazole consists of a pyrazole core substituted with a chloromethyl group at the 5-position and a 2,2-difluoroethyl group at the 1-position. The chloromethyl group (–CH?Cl) introduces reactivity that allows for further functionalization, while the difluoroethyl group (–C?F?) contributes to lipophilicity and metabolic stability. These structural features make the compound a versatile building block for drug discovery efforts aimed at developing novel therapeutic agents.

In recent years, there has been growing interest in pyrazole derivatives due to their demonstrated efficacy across multiple therapeutic areas. The fluorine atoms in the 2,2-difluoroethyl moiety are particularly noteworthy, as they are frequently employed in medicinal chemistry to enhance drug properties such as bioavailability, metabolic resistance, and binding affinity. The combination of these elements in 5-(chloromethyl)-1-(2,2-difluoroethyl)-1H-pyrazole suggests potential applications in the development of small-molecule inhibitors, ligands for enzyme or receptor targeting, and other bioactive compounds.

One of the most compelling aspects of this compound is its utility as a precursor in the synthesis of more complex molecules. The chloromethyl group serves as a handle for nucleophilic substitution reactions, enabling the introduction of diverse functional groups such as amines, alcohols, or thiols. This flexibility is crucial for generating libraries of compounds for high-throughput screening (HTS) or structure-activity relationship (SAR) studies. Similarly, the difluoroethyl group can be further modified through cross-coupling reactions or other synthetic methodologies to explore new chemical space.

Current research trends indicate that 5-(chloromethyl)-1-(2,2-difluoroethyl)-1H-pyrazole may find applications in the design of inhibitors targeting kinases and other enzymes involved in cancer pathways. Pyrazole derivatives have already shown promise in this area due to their ability to mimic natural substrates or bind to allosteric sites on target proteins. The fluorinated substituents may enhance binding interactions by improving hydrophobic matching or by modulating electronic properties at critical residues within the enzyme active site.

Additionally, the compound’s structural motif aligns with emerging trends in drug design that emphasize modularity and tunability. By leveraging its reactive sites, chemists can rapidly assemble novel analogs with tailored properties. For instance, modifications at the chloromethyl position could yield compounds with improved solubility or selectivity, while alterations around the difluoroethyl group might enhance pharmacokinetic profiles. Such adaptability is essential for addressing challenges posed by drug resistance or off-target effects.

The synthesis of 5-(chloromethyl)-1-(2,2-difluoroethyl)-1H-pyrazole itself presents an interesting challenge from a chemical standpoint. While no detailed synthetic routes have been widely published as of yet, plausible strategies might involve halogenation of a pyrazole precursor followed by introduction of the difluoroethyl group via Grignard-type reactions or metal-catalyzed cross-coupling. Given its structural complexity, optimizing yield and purity would require careful consideration of reaction conditions and purification techniques.

In academic and industrial settings alike, this compound is being explored as part of broader efforts to expand the pharmacophoric diversity available for drug discovery. Its unique combination of substituents positions it as a candidate for further derivatization into molecules with enhanced therapeutic potential. Collaborative projects between synthetic chemists and biologists are likely to yield insights into how modifications around this core scaffold can be exploited to develop next-generation therapeutics.

The role of computational chemistry in studying 5-(chloromethyl)-1-(2,2-difluoroethyl)-1H-pyrazole cannot be overstated. Molecular modeling techniques can predict binding affinities, identify potential interaction hotspots with biological targets, and guide experimental design. Such simulations are increasingly integral to modern drug development pipelines because they allow researchers to make data-driven decisions about which analogs warrant experimental validation.

Looking ahead, advancements in synthetic methodologies may enable more efficient access to derivatives of this compound than currently possible. For example, flow chemistry could provide scalable routes to complex pyrazole-based scaffolds while minimizing waste generation—a critical consideration given growing environmental concerns within pharmaceutical manufacturing. Similarly innovations in catalysis might streamline functionalization steps that would otherwise require multi-step sequences involving harsh reagents.

The ultimate success of 5-(chloromethyl)-1-(2,2-difluoroethyl)-1H-pyrazole will depend on how effectively it can be translated from laboratory research into clinical applications through rigorous testing and validation studies conducted according to regulatory guidelines established by agencies such as the FDA or EMA when appropriate regional approvals are sought after completion

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)